Molecular Diagnostics at the Point of Need
|
|
- Elisabeth Anthony
- 6 years ago
- Views:
Transcription
1 Molecular Diagnostics at the Point of Need 24 November 2016 David Budd CEO
2 1 DOCUMENT INFORMATION The information contained in this document and made verbally to you (together the Presentation ) is confidential and is being supplied to persons with professional experience in matters relating to investments and/or to high net worth companies as described in Article 19(5) and 49(2) respectively of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 (SI. 2001/No.1335) (as amended) made pursuant to section 21(5) of the Financial Services and Markets Act 2000 and, if permitted by applicable law, is being supplied outside the United Kingdom to professionals or institutions whose ordinary business involves them in investment activities. The information contained in this document is not intended to be viewed by, or distributed or passed on (directly or indirectly) to, any other class of persons. Accordingly, information contained in the Presentation is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person or published in whole or in part, for any purpose. In particular, the distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction. No representation or warranty, express or implied, is given as to the accuracy of the information or opinions contained in the Presentation and no liability is accepted for any such information or opinions by genedrive plc (the Company ) or any of its directors, members, officers, employees, agents or advisers. Notwithstanding this, nothing in this paragraph shall exclude liability for any representation or warranty made fraudulently. The Presentation does not constitute any part of an offer of, or invitation to apply for, securities in the Company.
3 2 COMPANY OVERVIEW GENEDRIVE PLC (LSE:GDR) Rapidly developing, commercial-stage molecular diagnostics business Company based in Manchester. Renamed genedrive plc July 2016 Refocusing on a Healthcare Diagnostics business model Raised c. 6.0m in July 2016 Develop test portfolio, clinical trials, expand commercialisation efforts, increase operational infrastructure New management team Diagnostics and commercial experience and track record Genedrive : a Point-of-Need, molecular diagnostic system Focus on market opportunities where DNA analysis can be used to diagnose and treat patients Large attractive markets exist (c.$1bn for infectious disease pipeline) But today are generally delivered from expensive, hospital based settings
4 3 COMPANY OVERVIEW GENEDRIVE PLC (LSE:GDR) Rapidly developing, commercial-stage molecular diagnostics business Genedrive Decentralised Molecular Diagnostics using handheld Genedrive system Contract Research Organisation Provides Services to Pharmaceutical Industry and Biotech to understand biochemical pathways during drug development Pharmacogenomics Organisation Provides Services to Pharmaceutical and Biotech to understand genetic modes of drug action & activation during drug development
5 4 MOLECULAR DIAGNOSTICS Molecular diagnostic tests detect specific sequences in human genes or the DNA of microbes, viruses and pathogens that may be associated with disease Use a technique called PCR, that takes a tiny amount of DNA from cells and replicates it to a quantity that we can analyst Understanding DNA can mean getting the most appropriate treatment as quickly as possible Historically provided almost exclusively from large hospital labs or specialised testing centres
6 5 GENEDRIVE TECHNOLOGY Technology platform brings the power of molecular diagnostics outside of the hospital Affordable System and test cost price point accessible world-wide Rapid results outside of a hospital environment Prompt clinical decisions are possible - sample to result typically in minutes Easy to use Single use disposable reagent cartridge (razor/ razor blade model) Limited training required for operation Real world robustness and reliability Battery pack permits use in poor infrastructure settings Operates in hot and humid conditions present outside laboratories Versatile Core technology across a range of applications, including human health, animal health, and environmental testing
7 6 APPLICATIONS BACTERIAL INFECTIONS - TB Tuberculosis (TB) is a global healthcare crisis with 9.6m new cases in 2014 TB is the largest single infectious cause of death among young people and adults Poor and inappropriate treatments historically has led to widespread drug resistance TB diagnosis in many countries is still reliant on old fashioned microscopy Variable by operator and can be less that 60% - 80% sensitive in correctly diagnosing TB It tells you nothing about drug resistance. Culture = 40 days Molecular testing with Genedrive 33% 13% 2% India 52% China South Africa Brazil Percent of New Active TB Cases in 2012 in the High Burden Countries Determine TB infection status and resistance to Rifampicin No operator interpretation Quick results at a Point of Need
8 7 Decentralising molecular diagnostics APPLICATIONS BACTERIAL INFECTIONS TB Predominantly public Fully automated Large Hospital KOLs Hospital High Throughput/ Low PoC usage Labs (n=500) Small/ Medium Labs (n=5,000) Small Out-Reach Labs (n=50,000) Predominantly private Manual Low Skill Level Medium Point of Need use Predominantly public Semi-automated Medium Skill Level High PoC usage Of the TB tests currently conducted, Genedrive has shown 95% sensitivity, and 94% specificity with respect to culture confirmed microscopy. This is fully aligned to the company s performance claims.these results show that Genedrive offers an acceptable, low cost and accessible alternative for facilities without the sophisticated infrastructure and equipment which we have in our main laboratory. Dr Bhavini Shah, Head of TB testing services at Supratech Inc, India Indian market launch Genedrive test launched under licence from Drug Controller General of India Commercial approach Market accessed through distribution partner Xcelris Laboratories Ltd Target market Simple market segmentation of laboratories in India Initially targeting small/medium laboratories in private sector
9 8 APPLICATIONS VIRAL INFECTIONS HCV Hepatitis C (HCV) is a growing global healthcare crisis with c.170m people infected globally Historically treatment was very expensive and only effective on a subset of patients Required molecular testing and different treatments based on their DNA and the DNA of the virus China India Egypt Pakistan Indonesia Russia USA New Direct Activing Antiviral drugs are very effective and in most cases curative D.R. Congo Nigeria Japan New demand for molecular testing to determine if someone is infected with HCV virus Diagnosis rate in some countries is <10% Cameroon Brazil Uganda Ukraine Molecular Testing with Genedrive Italy Phillipines Genedrive HCV-ID can be used in decentralised laboratories to provide testing to those that don t have access Rapid result in <90 minutes Uzbekistan Thailand Ethiopia Turkey
10 9 APPLICATIONS HUMAN GENOTYPING Molecular diagnostic applied to individual genetics Determine if a person is likely to respond to treatment. Some new cancer drugs are only effective on a subset of patients, requiring the use of a Companion Diagnostics product Out of 45 new drugs approved by the FDA in 2015, 13 require a companion diagnostic test 30% of all treatments in late clinical development rely on biomarker data Molecular Testing with Genedrive genedrive plc s first human genotyping test, IL28B, was CE certified in November 2016 IL28B companion diagnostic validates Genedrive platform for use in pharmacogenomics/companion diagnostics
11 10 APPLICATIONS BIO-DEFENSE PATHOGEN ID Agreement with the US Department of Defense to develop Genedrive as a handheld bio-agent identifier testing system Identification of biological agents and pathogens in a military setting US DoD began assessing Genedrive for biodefence use in 2011 Positive review was followed up by US$7.8m in milestone funding due over 5 years (US$2.4m in 2016) $2.9m extension was confirmed in March 2016 Molecular Testing with Genedrive Specific Application of Genedrive is Confidential but it is anticipated it could be deployed in laboratory, non laboratory, or field applications
12 11 APPLICATIONS AGRICULTURE CROP LOSS Collaboration with Centre for Environment, Fisheries & Aquaculture Sciences (CEFAS) Point-of-need aquaculture test for diagnosis of pathogens Main target identified: White Spot Syndrome Virus Point of need aquaculture test for diagnosis of pathogens Affects shrimps/ crustaceans and can wipe out entire shrimp farms within days Estimated at ~$US 1B annual loss Molecular Testing with Genedrive 0.4m grant funding for test development from Innovate UK Determination of White Spot infection on-site in less than 60 minutes
13 12 DE-RISKED AND DIVERSE APPLICATIONS
14 13 COMMERCIAL OPPORTUNITIES AND STRATEGY Genedrive is an effective, low cost, molecular solution across a broad range of applications Genedrive - Internally Develop and Drive Proprietary Menu MTB/RIF > $120m in top 4 markets HCV > $500m diagnostics market broad application to other blood borne viruses (HIV, HEP B) Genedrive - Externally Develop and Drive Open or Proprietary Menu Migrate established assays to Genedrive platform Leverage Open Innovation Partnerships Critical or competitive menu item BD opportunities with DX and Pharma
15 OPERATIONAL HIGHLIGHTS Initial launch of the Genedrive Tuberculosis (MTB/RIF) assay in India in April/May 2016 Early days but Interest from the market has been encouraging Development programme of the Genedrive Hepatitis C (HCV) accelerated CE-IVD approval of the HCV test scheduled for March/April 2017 Successful progress in US Department of Defense Programme Develop Genedrive biohazard identification tests triggered by successful progress
16 OPERATIONAL HIGHLIGHTS (CONTINUED) Successful Genedrive validation for aquaculture Detection of White spot disease in shrimps in collaboration with the Centre for Environment, Fisheries and Aquaculture Science (CEFAS). Currently in field validation in Thailand Successful Genedrive validation for Human Genotyping Successful clinical trial results of Genedrive IL28B genotyping test in conjunction with Institut Pasteur and adoption of the Genedrive IL28B test in clinical trials being conducted by STOP- HCV campaign CE-IVD marked November 2016 Review and redirection of Group management organisation focussing the Company on the Genedrive molecular diagnostics opportunities Detailed strategic review of the Company s Preclinical & Pharmacogenomics Services operations commenced
17 16 FINANCIAL REVIEW PRELIMINARY RESULTS 2016 Full year revenues at 5.0m, up from 4.5m driven by Genedrive development income Revenues 5.0m 4.5m Preclinical Research revenues at 2.0m, down from 2.3m Pharmacogenomic revenues of 1.1m from 1.2m Contract costs 3.3m 3.9m Diagnostics Genedrive revenues of 1.9m up from 0.9m, based on development revenues from US DoD. Net Genedrive development investment of 2.9m Discovery, development and admin expenses 7.2m 4.6m Full year Operating loss of 5.4m reflecting increased Administrative costs of 2.4m End June cash balance 1.1m, bolstered in July 2016 by 6.0m net proceeds of Placing Operating loss for the full year (5.4)m (4.0)m Cash reserves 1.1m 30 June 2016 With Placing proceeds 4.9m 7.1m
18 17 SUMMARY Rapidly developing commercial-stage molecular diagnostics business 1 Genedrive is a disruptive point-of-need molecular diagnostic system 2 Strong management team with diagnostics and commercial experience and track record 3 Addressing multiple large markets ($1bn for infectious disease pipeline) 4 Plan to accelerate menu development through in house programmes and an actively seeking Partnerships 5 Newsflow: TB progress in India, HCV approval and roll out EU, Distribution, Corporate Partnerships
19 18 THANK YOU
Molecular Diagnostics for Global Heath Problems. Proactive Investors Forum 5 October 2017
Molecular Diagnostics for Global Heath Problems Proactive Investors Forum 5 October 2017 2 Document Information The information contained in this document and made verbally to you (together the Presentation
More informationAlere q. A platform to answer global health needs: TB and beyond. Duncan Blair Director, Public Health Initiatives
Alere q A platform to answer global health needs: TB and beyond Duncan Blair Director, Public Health Initiatives 7 th FIND Symposium, Barcelona, October 2014 Alere q platform overview Comprising the Alere
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationChallenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationUBS Global Life Sciences Conference
September 21, 2010 UBS Global Life Sciences Conference Tecan Group AG Thomas Bachmann, CEO September 21, 2010 / p2 / UBS Global Life Sciences Conference Introducing Tecan Provider of instruments and workflow-solutions
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationGenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING. J.P. Morgan Healthcare Conference 2018
GenMark Diagnostics TRANSFORMING MULTIPLEX MOLECULAR TESTING J.P. Morgan Healthcare Conference 2018 1 Forward-Looking Statements This presentation contains forward-looking statements about GenMark Diagnostics,
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationFor personal use only
Shareholder Presentation Perth, WA Annual General Meeting 17th November 2016 Global leader in applying proteomics to MedTech ASX: PIQ 1 Disclaimer & forward-looking statements This Presentation is provided
More informationBRIC Surgical Sutures Market Outlook to 2020
BRIC Surgical Sutures Market Outlook to 2020 Reference Code: GDMECR0270DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationFuture of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities
Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities Introduction The report analyzes current and potential world molecular diagnostics markets and advances in the field.
More informationHIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005
HIKMA PHARMACEUTICALS PLC Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005 Important notice This document and its contents are confidential and may not be redistributed or
More informationDiagnostics for Utopia. Company Introduction
Diagnostics for Utopia Company Introduction Contents SUMMARY Ⅰ. Current Status of the Company Ⅱ. IVD Market Trends & Future Forecast Ⅲ. Market Analysis and Marketing Strategy Ⅳ. Company Location 1 SUMMARY
More informationDiagnostics gathering intelligence to fight antimicrobial resistance
Diagnostics gathering intelligence to fight antimicrobial resistance Arjon van Hengel European Commission DG Research and Innovation, Health Directorate Unit "Fighting Infectious Diseases and Advancing
More informationAbcam Plc. JP Morgan Healthcare Conference January 2017
Abcam Plc JP Morgan Healthcare Conference January 2017 2 Disclaimer Important information The information provided in this presentation is for the sole use of those attending the presentation; it shall
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationMr. Lou Panaccio Executive Chairman
Mr. Lou Panaccio Executive Chairman 1 Overview Objective Develop compelling multiplexed test solutions for the $4BN global molecular diagnostic testing industry using our silica bead based AmpaSand technology
More information35th Annual J.P. Morgan Healthcare Conference
35th Annual J.P. Morgan Healthcare Conference Investor Presentation Nachum Homi Shamir President and Chief Executive Officer January, 2017 Safe Harbor Statement Certain statements made during the course
More informationBio-Pharma: China A Look at The FUTURE: 4 th & 5 th Generation Global Strategies
Global Strategy Global Challenges Executable Solutions Bio-Pharma: China 2010-2020 A Look at The FUTURE: 4 th & 5 th Generation Global Strategies France Houdard Managing Director January 2010 Table of
More informationUBS Global Life Sciences Conference
September 20, 2011 UBS Global Life Sciences Conference Tecan Group AG Dr. Rudolf Eugster, CFO September 20, 2011 / p2 / UBS GLSC Contents Introducing Tecan Strategic Growth Drivers Financials H1 2011 &
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationE2ES to Accelerate Next-Generation Genome Analysis in Clinical Research
www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution
More informationPositioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory. Giorgio Roscigno CEO FIND
Positioning of TB Diagnostics within a Tiered System Integrated Approach from Reference to District Laboratory Giorgio Roscigno CEO FIND Integrated Laboratory Network Definition An integrated laboratory
More informationBiocartis: pushing boundaries in healthcare. Hilde Windels Dag van de Tips 10 October 2015
Biocartis: pushing boundaries in healthcare Hilde Windels Dag van de Tips 10 October 2015 2 NOTICES AND WARNINGS This presentation has been prepared by the management of Biocartis Group NV (the "Company").
More informationPortable breath analyser for rapid TB detection
24 Rapid Biosensor s Breath Analyser is able to detect the presence of TB bacilli in a cough deposited onto a biochemically coated sensor. TB can be indicated in only two minutes compared with hours or
More informationSelection and use of Ebola in vitro diagnostic (IVD) assays
EMERGENCY GUIDANCE Selection and use of Ebola in vitro diagnostic (IVD) assays June 2015 World Health Organization 2015. All rights reserved. The designations employed and the presentation of the material
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationDIAGNOSTIC R&D FOR NEGLECTED DISEASES
G-FINDER FACTSHEET DIAGNOSTIC R&D FOR NEGLECTED DISEASES Malaria samples being prepared for FIND s Rapid Diagnostic Test product testing project (Photo by Sandra Incardona) Effective diagnostics are essential
More informationGlobal In-Vitro Diagnostic Market Report
Global In-Vitro Diagnostic Market Report ----------------------------------------------------- 2013 Executive Summary The process of performing a diagnostic test outside of a living organism in an artificial
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationDIAGNOSTICS: COLLECTION TO DETECTION. Results that matter.
DIAGNOSTICS: COLLECTION TO DETECTION Results that matter. LEADING THE WAY IN DIAGNOSTIC SOLUTIONS Diagnostics is the dynamic, growing industry that relies on faster and more accurate results to improve
More informationThis is a licensed product of Ken Research and should not be copied
1 TABLE OF CONTENTS 1. India In-Vitro Diagnostics Market Introduction Market Overview Growth Drivers Constraints Regulatory Framework and Accreditation 2. India In-Vitro Diagnostics Market Size by Revenues,
More informationQuantStudio Dx Real-Time PCR Instrument
QuantStudio Dx Real-Time PCR Instrument Behind every diagnosis, there is a promise You believe in molecular medicine. So do we. We are committed to providing you with comprehensive solutions that help
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationKonica Minolta to Acquire Invicro (US)
Konica Minolta to Acquire Invicro (US) Acceleration of expansion of precision medicine business Offering new value for drug discovery and development in immuno-oncology and neurodegenerative disease September
More informationMoving from volume to value in the generic business model
Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating
More informationProteomics International Laboratories Ltd
Proteomics International Laboratories Ltd PIQ: ASX: A$0.24 Recommendation: Buy Price Target: A$0.45 retained Launch of its PromarkerD diagnostic test in February 2018 Potential strong deal flow and cash
More informationWHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.
June 2017 WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES. 3rd most populous country 50% of affected are children
More informationMay 14, 2014 CGI Announces Acquisition of BioServe India
Empowering Personalized Cancer Treatment May 14, 2014 CGI Announces Acquisition of BioServe India CGI and BioServe India Enter Into Acquisition Agreement On May 14 th, 2014 Cancer Genetics, Inc. and BioServe
More informationRecent Approaches in Detection of Drug- Resistant Tuberculosis. Dr M Hanif Bacteriologist Laboratory Division New Delhi Tuberculosis Centre
Recent Approaches in Detection of Drug- Resistant Tuberculosis Dr M Hanif Bacteriologist Laboratory Division New Delhi Tuberculosis Centre Newer Diagnostic Methods for MDR TB Rapid Culture and DST using
More informationOwn the future As molecular testing evolves, so can you
Own the future As molecular testing evolves, so can you Not for distribution in the US; not available in all markets. cobas 8800 System Introducing the cobas 6800 and 8800 Systems Redefining molecular
More informationUpdate on quality management using EQA and RemoteXpert
Update on quality management using EQA and RemoteXpert 1. Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Science, and NHLS, South Africa 2. Management Sciences
More informationInvestor Presentation
Investor Presentation 2017 www.enzo.com LEGAL DISCLAIMER Except for historical information, the matters discussed herein may be considered "forward looking" statements within the meaning of Section 27A
More informationFirms and Federal Labs Flock to Seek FDA Emergency Use Authorization for Ebola MDx Assays
Firms and Federal Labs Flock to Seek FDA Emergency Use Authorization for Ebola MDx Assays October 21, 2014 Firms and Federal Labs Flock to Seek FDA Emergency Use Authorization for Ebola MDx Assays By Madeleine
More informationAligning Lab Goals & Institutional Goals Laughlin Rice
Aligning Lab Goals & Institutional Goals Laughlin Rice Senior Administrative Director Department of Pathology & Laboratory Medicine The Children s Hospital of Learning Objectives To understand the institutional
More informationPolicies that encourage innovation in middle-income countries
December 2012 Policies that encourage innovation in middle-income countries The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) asked Charles River Associates (CRA) to
More informationTuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
More informationUpdate on the IVDR. Sue Spencer
Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application
More informationThe New EU IVDR. Overview of the Main Changes & Clinical Data Requirements. Advance Regulatory Consulting Ltd.
Overview of the Main Changes & Clinical Data Requirements Advance Regulatory Consulting Ltd. : Timeline: Entry in to force Q2 (Apr) 2017 Adoption: +6m NB s apply for designation IVDs classified as Class
More informationASIT BIOTECH ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS AND EURONEXT PARIS
This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for securities. This announcement is not a prospectus
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationNeue Technologien für die patientennahe personalisierte Diagnostik
Neue Technologien für die patientennahe personalisierte Diagnostik 2014 Dr. Soeren Schumacher, M.B.A. 27th of June 2014 1 A heterogeneous pool 27th of June 2014 2 A heterogeneous pool Personalized Medicine
More informationA LentiVector Platform Company, and a leader in gene and cell therapy. Annual General Meeting 23 May 2017
A LentiVector Platform Company, and a leader in gene and cell therapy Annual General Meeting 23 May 2017 Forwardlooking statements This presentation does not constitute an offer to sell or a solicitation
More information+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA
At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world
More informationZIKAVAX PARTNERSHIP. Dr Odile LEROY DCVMN Seoul 26 th September 2017
ZIKAVAX PARTNERSHIP Dr Odile LEROY DCVMN Seoul 26 th September 2017 1 Product Development Partnership THE EUROPEAN VACCINE INITIATIVE IS A PRODUC T DEVELOPMENT PARTNERSHIP WHICH AIMS TO ACCELERATE THE
More informationAlmac Overview.
Almac Overview www.almacgroup.com 2 Welcome to Almac 3 Who is Almac? Almac is a world leading drug development & commercial services company; providing an expanding array of innovative solutions worldwide
More informationHow to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations. The complete guide to developing or expanding your lab
How to Build a Molecular Testing Laboratory: Key Strategic & Operational Considerations The complete guide to developing or expanding your lab Includes step-by-step plans for basic and full-service MDx
More informationFor personal use only
ASX ANNOUNCEMENT Non-Deal Roadshow Presentation 25 May 2015 Sydney, 25 May 2015: Genetic Signatures (ASX: GSS) is pleased to release a copy of the presentation that John Melki, PhD., Director & CEO and
More informationStool GeneXpert MTB/Rif Assay
Stool GeneXpert MTB/Rif Assay Standard Operating Procedure 1.0. Purpose The purpose of this standard operating procedure (SOP) is to detail the steps for correctly performing, interpreting, and documenting
More informationBIOCRATES Life Sciences AG Short Company Presentation
BIOCRATES Life Sciences AG Short Company Presentation Dr. Alexandra C. Gruber MBA MMFin Director Business Development / Marketing Austria Showcase Life Science Japan, Tokyo, December 2010 BIOCRATES Life
More informationFacilitating local production for improved access to in vitrodiagnostics. Tuberculosis. Ruth McNerney. Ruth McNerney & Rosanna Peeling
Tuberculosis Facilitating local production for improved access to in vitrodiagnostics Ruth McNerney & Rosanna Peeling Ruth McNerney London School of Hygiene & Tropical Medicine Department of Pathogen Molecular
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationNanotechnology and Advanced Materials for more effective Healthcare
Nanotechnology and Advanced Materials for more effective Healthcare This challenge taps into the potential of nanotechnologies and advanced materials to enable more effective therapies and diagnostics
More informationIon S5 and Ion S5 XL Systems
Ion S5 and Ion S5 XL Systems Targeted sequencing has never been simpler Explore the Ion S5 and Ion S5 XL Systems Adopting next-generation sequencing (NGS) in your lab is now simpler than ever The Ion S5
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More informationDecision Tree for selection of model agreements for collaborative commercial clinical research
Decision Tree for selection of model agreements for collaborative commercial clinical research 1 Research interactions involving industry, universities and the NHS Industry, universities and the NHS cooperate
More informationAssessing quality-assured diagnoses made by TB laboratories
Assessing quality-assured diagnoses made by TB laboratories Quality-assured TB laboratory Objectives: at the end of the assessment reviewers should comment on the laboratory network and its structure;
More informationForecast diagnostics for antimicrobial resistance (AMR)
Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford Context When asked to make forecasts
More informationPharmaceutical Product Development NASDAQ: PPDI. Dan Darazsdi Chief Financial Officer. Credit Suisse Healthcare Conference November 2009
Pharmaceutical Product Development NASDAQ: PPDI Dan Darazsdi Chief Financial Officer Credit Suisse Healthcare Conference 2009 12 November 2009 Safe Harbor Except for historical information, all of the
More informationBiopharmaceuticals Investor & Analyst Day
Adequate picture Biopharmaceuticals Investor & Analyst Day Strategic perspective on Merck KGaA, Darmstadt, Germany Karl-Ludwig Kley CEO Darmstadt, Germany September 18, 2014 Disclaimer Remarks All comparative
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationAdvertising and Marketing Genetic Tests New Pathways or Old Roads?
Advertising and Marketing Genetic Tests New Pathways or Old Roads? Kathleen M. Sanzo, Morgan Lewis FDLI Advertising & Promotion Conference Wednesday, September 28, 2016 Context for Use of Genetic Tests
More informationHow to Choose the Right Equipment/Platforms for your Laboratory
How to Choose the Right Equipment/Platforms for your Laboratory (A Public Hospital Laboratory Perspective) Michelle J. Francis Overview Public Hospital Pressures / Challenges Commercial vs In-house assays
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationAkers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers
Akers Biosciences, Inc. Screening and testing technologies that deliver rapid health information to consumers and healthcare providers 1 All statements pertaining to future financial and/or operating results,
More informationStrengthening the experience and embracing the shift
Strengthening the experience and embracing the shift THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES. IT IS SOLELY FOR USE AT A CAPITAL MARKETS EVENT AND IS PROVIDED
More informationGENERAL PAYER CONSIDERATIONS FOR NEW HEALTH TECHNOLOGIES (INCLUDING DIAGNOSTICS)
FORUM Payer perspectives and actions impacting diagnostics in the US and Europe Eric Faulkner, MPH Director, Quintiles Global Market Access Consulting; Executive Director, Genomics Biotech Emerging Medical
More informationLife Sciences Online Courses
Life Sciences Online Courses Table Of Contents Table of Contents How to Register 3 Learn Biotechnology Online 4 Learn MedDevice Online 5 Learn Molecular Diagnostics Online 6 Learn Biosafety & Biorisk Online
More informationEARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles
EARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles BrainDTech team Dr. Fabio Bianco, PhD Chief Executive Officier PhD in Pharmacology, Degree in Biotech
More informationFour entry strategies for small and midsized companies
White paper >7,100 sales reps >220 product launches in 20 countries supported since 2009 Emerging markets: Four entry strategies for small and midsized companies Executive summary Emerging markets offer
More informationAPITOPE ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND LISTING ON EURONEXT BRUSSELS
APITOPE ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL PUBLIC OFFERING AND LISTING ON EURONEXT BRUSSELS HASSELT, Belgium, and CHEPSTOW, UK, 31 October 2017 - Apitope (the Company or Apitope ), a clinical
More informationInnovate 2 Succeed Invitation to Tender External Evaluator - June 2017
1. Introduction: Innovate 2 Succeed Invitation to Tender External Evaluator - June 2017 1.1 Invitation to Tender This is an invitation to submit a tender to provide services ( Services ) to meet the requirements,
More informationFull year results Amsterdam, 5 February 2015
Full year results 2014 Amsterdam, 5 February 2015 Disclaimer The information contained herein shall not constitute or form any part of any offer or invitation to subscribe for, underwrite or otherwise
More informationInvestor Presentation
Siemens Ltd., 2 www.siemens.co.in Disclaimer This presentation has been prepared solely for use at the investor/analyst presentation. By attending the meeting where this presentation is made, or by reading
More informationClassification under the IVD Regulation
Classification under the IVD Regulation Nick Baker Head of IVD Notified Body LRQA Ltd Improving performance, reducing risk IVD regulation shift in regulatory scrutiny Under the current IVD directive 10-15%
More informationPhilips Capital Your one-stop financing resource. Philips Capital May, 2016
Your one-stop financing resource May, 2016 Contents How we can help grow your business Sources and solutions Long-term partnerships Best practises Case studies Summary 2 For more than 120 years, Philips
More informationThe In Vitro Diagnostic CRO
The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro
More informationWhat it takes to make a new state of the art diagnostics platform for Point of Care use.
What it takes to make a new state of the art diagnostics platform for Point of Care use. 31.10.2006 Axis-Shield plc 450 employees Turnover 58 million Profit before tax 1,9 million R&D spend 7,4 million
More information